Tiziana Life Sciences Ltd. filings document foreign-private-issuer material-event disclosures for a clinical-stage biotechnology company developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company’s Form 6-K reports furnish press-release exhibits on clinical and preclinical data, biomarker findings, peer-reviewed study publications, conference presentations, and program activity in neuroinflammatory and neurodegenerative diseases.
The filing record also includes capital-structure disclosures tied to registered direct offerings of ordinary shares and warrants, together with governance and security-structure information relevant to the company’s Nasdaq-listed ordinary shares and foreign issuer reporting framework.
Tiziana Life Sciences Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, purchased 15,000 shares of common stock in an open-market transaction at $1.11 per share on June 12, 2026, bringing indirect holdings to 44,772,230 shares. This amended report updates only the transaction code associated with that purchase.
Tiziana Life Sciences Ltd Chief Executive Officer Ivor Elrifi, through a trust, purchased a total of 321,423 shares of common stock in two open-market or private transactions. The trust bought 237,616 shares at $1.00 per share on August 5, 2026 and 83,807 shares at $0.97 per share on August 4, 2026. The holdings are reported as indirect, "By trust", and the Rule 10b5-1 trading-plan checkbox is not marked.
Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on Nasdaq at $1.00 per share, increasing his holdings to 4,793,684 shares.
The company also highlights its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody being developed for neuroinflammatory and neurodegenerative diseases. Fourteen patients with non-active secondary progressive multiple sclerosis have received intranasal foralumab in an open-label Expanded Access Program, with either improvement or stability of disease observed within six months in all patients. Intranasal foralumab is additionally being studied in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in the same indication.
Tiziana Life Sciences Ltd reported that Chief Executive Officer Ivor Elrifi, through a trust, purchased 667,000 shares of common stock on 2026-08-03 at 1.0000 per share in an open-market or private transaction. Following this purchase, his indirectly held stake by trust is 4,472,261 shares.
Tiziana Life Sciences Ltd reports that Chief Executive Officer Ivor Elrifi has increased his stake by purchasing 667,000 common shares on Nasdaq at $1.00 per share, bringing his total holding to 4,472,261 common shares.
The company is a clinical-stage biotechnology firm focused on immunomodulation therapies, led by intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Fourteen patients with non-active secondary progressive multiple sclerosis have been dosed in an Expanded Access Program, all showing improvement or disease stability within six months, and a Phase 2a randomized, double-blind, placebo-controlled trial is ongoing.
Tiziana Life Sciences reported quantitative PET imaging data from a third Multiple System Atrophy (MSA) patient in a Phase 2 trial of intranasal foralumab. PET scans showed up to 34% reduction in SUV and 26% reduction in SUVR in disease‑relevant regions such as the basal ganglia and cerebellar white matter.
These reductions are similar to those seen in the first two MSA patients, which showed up to approximately 35% SUV and 24% SUVR decreases, supporting PET imaging evidence of biological activity in dampening neuroinflammation. Tiziana also reports that 14 patients with non‑active secondary progressive multiple sclerosis in an expanded access program have all shown improvement or stability within six months after intranasal foralumab.
Tiziana Life Sciences Ltd director and chief executive officer Ivor Elrifi filed an initial statement of beneficial ownership. He reports direct ownership of 3,805,261 shares of common stock and restricted stock units linked to 3,150,000 underlying common shares.
These restricted stock units are reported with a conversion or exercise price of $1.26 per share, first exercisable on 2026-08-15 and expiring on 2028-08-15. Remarks state that 1,050,000 RSUs will vest annually over three years.
Tiziana Life Sciences Ltd reported that director and ten percent owner Gabriele M. Cerrone, holding indirectly via Panetta Partners Limited, received a grant/award of 42,357 shares of common stock on July 21, 2026 at $0.99 per share. Following this indirect acquisition, his associated holdings total 44,814,587 common shares.
Tiziana Life Sciences Ltd reported that Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 42,357 common shares at $0.99 per share. Following this transaction, his total holding is 44,814,587 common shares, representing 34.93% of issued share capital.
The company highlights its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody in development for neuroinflammatory and neurodegenerative diseases. Fourteen patients with non-active secondary progressive multiple sclerosis have been dosed in an Expanded Access Program, with improvement or disease stability within 6 months in all patients, and a Phase 2a randomized, double-blind, placebo-controlled trial is ongoing.
Tiziana Life Sciences reports that the last patient in its Phase 2a INFORM-MS trial has received a first dose of intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks full initial dosing in the randomized, double-blind, placebo-controlled study.
The trial will evaluate two intranasal foralumab dose levels versus placebo in up to 48 patients across multiple U.S. centers, using imaging biomarkers and clinical outcomes. The primary endpoint is change in microglial activation measured by PET scans, alongside disability, fatigue, and quality-of-life measures.
Topline data are expected in late Q3 or early Q4 2026 and are planned to be presented at the joint ACTRIMS/ECTRIMS meeting in Toronto in October 2026. Separately, 14 na-SPMS patients in an expanded access program have shown improvement or disease stability within six months after intranasal foralumab treatment.